Literature DB >> 1118185

Genetic studies on Plasmodium chabaudi: recombination between enzyme markers.

D Walliker, R Carter, A Sanderson.   

Abstract

Two lines of Plasmodium chabaudi differing in three characters have been crossed, using a technique previously described for P. yoelii. One line, termed 47AS, was characterized by an electrophoretic form of 6-hosphogluconate dehydrogenase, denoted 6PGD-2, a form of lactate dehydrogenase, denoted LDH-3, and was pyrimethanime-resistant. The second line, termed 10AJ, possessed enzyme forms of 6PGD-3 and LDH-2 and was pyrimethamine-sensitive. The cross was made by permitting mosquitoes to feed on a mixture of the two lines and infecting rodents with the resulting sporozoites. The products of the cross were cloned by dilution and examined for enzyme-type and drug-response. Results showed that recombination had occurred between each of the three characters. Clones characterized by 6PGD-2/LDH-2 and 6PGD-3/LDH-3 demonstrated recombination between the enzyme markers. The drug-resistance character segregated independently of either enzyme marker.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1118185     DOI: 10.1017/s0031182000048824

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  36 in total

1.  Antimalarial drugs clear resistant parasites from partially immune hosts.

Authors:  P Cravo; R Culleton; P Hunt; D Walliker; M J Mackinnon
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

2.  Genetics of mefloquine resistance in the rodent malaria parasite Plasmodium chabaudi.

Authors:  Pedro V L Cravo; Jane M-R Carlton; Paul Hunt; Laura Bisoni; Rose Ann Padua; David Walliker
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

3.  Chemotherapy, within-host ecology and the fitness of drug-resistant malaria parasites.

Authors:  Silvie Huijben; William A Nelson; Andrew R Wargo; Derek G Sim; Damien R Drew; Andrew F Read
Journal:  Evolution       Date:  2010-08-19       Impact factor: 3.694

4.  The fitness of drug-resistant malaria parasites in a rodent model: multiplicity of infection.

Authors:  S Huijben; D G Sim; W A Nelson; A F Read
Journal:  J Evol Biol       Date:  2011-08-23       Impact factor: 2.411

5.  Antifolate drug selection results in duplication and rearrangement of chromosome 7 in Plasmodium chabaudi.

Authors:  A F Cowman; A M Lew
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

6.  Gametocyte development of Plasmodium chabaudi in mice and rats: evidence for host induction of gametocytogenesis.

Authors:  A W Cornelissen; D Walliker
Journal:  Z Parasitenkd       Date:  1985

7.  Sulfadoxine-pyrimethamine resistance in the rodent malaria parasite Plasmodium chabaudi.

Authors:  Karen Hayton; Lisa C Ranford-Cartwright; David Walliker
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b gene.

Authors:  Ana Afonso; Zoraima Neto; Helena Castro; Dinora Lopes; Ana C Alves; Ana M Tomás; Virgílio D Rosário
Journal:  Malar J       Date:  2010-05-21       Impact factor: 2.979

9.  Experimental evolution, genetic analysis and genome re-sequencing reveal the mutation conferring artemisinin resistance in an isogenic lineage of malaria parasites.

Authors:  Paul Hunt; Axel Martinelli; Katarzyna Modrzynska; Sofia Borges; Alison Creasey; Louise Rodrigues; Dario Beraldi; Laurence Loewe; Richard Fawcett; Sujai Kumar; Marian Thomson; Urmi Trivedi; Thomas D Otto; Arnab Pain; Mark Blaxter; Pedro Cravo
Journal:  BMC Genomics       Date:  2010-09-16       Impact factor: 3.969

10.  Expression of GIMAP1, a GTPase of the immunity-associated protein family, is not up-regulated in malaria.

Authors:  Amy Saunders; Tracey Lamb; John Pascall; Amanda Hutchings; Carine Dion; Christine Carter; Lucy Hepburn; Jean Langhorne; Geoffrey W Butcher
Journal:  Malar J       Date:  2009-04-02       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.